News

Pfizer has responded to criticism over the prices it has agreed to supply its pneumococcal vaccine Prevenar 13 to the Global Alliance for Vaccines and Immunisation (GAVI) alliance for children in the world’s poorest countries.

Pfizer has unveiled plans to internally carve up its business into three different sections, in a move designed maximise the value of its entire portfolio.

US regulators will carry out a speedy review of Depomed and Mallinckrodt’s experimental pain drug MNK-795.

Consumer and campaign groups have condemned as too little, too late new commitments made by industry in Europe and the US to widen access to clinical-trial data.

The market for disease-modifying multiple sclerosis therapies will expand at an annual rate of 10% to 2018, peaking at nearly $21 billion that year, say new forecasts.

Survival for testicular cancer has risen by almost 30% in the last 40 years, with nearly all men now beating the disease, according to figures published by Cancer Research UK.

Novartis’ new chronic obstructive pulmonary disorder therapies Ultibro Breezhaler and Xoterna Breezhaler are a massive step closer to winning European approval after an endorsement by the EMA’s Committee for Medicinal Products for Human Use.

Perrigo is buying Elan Corp for $8.60 billion in a deal that will give the US healthcare firm a base in tax-friendly Ireland.

UK researchers have discovered a new molecule that kills off cancer cells by starving them of oxygen, offering a new target for treating the disease.

The recent US Supreme Court decision on pay-for-delay payments puts the Federal Trade Commission in a much stronger position to go after such deals, a Senate panel has heard.

Pfizer has suffered a major setback after advisors to the European Medicines Agency again rejected Xeljanz for rheumatoid arthritis.

The European Commission has opened an “in-depth” inquiry into a scheme offering assistance to German pharmaceutical companies which are in financial difficulties.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has finalised a review of GLP-1-based diabetes therapies and concluded that “presently available data do not confirm recent concerns over an increased risk of pancreatic adverse events with these medicines”.

Shire shares have soared on the back of a strong set of second-quarter figures which saw net income up 8.5% to $258.1 million, while revenues rose 7% to $1.23 billion, ahead of analyst estimates.

The US Food and Drug Administration has approved Forest Laboratories and Pierre Fabre’s Fetzima for major depressive disorder.